Cargando…
Cost of Managing Type 2 Diabetes Before and After Initiating Dipeptidyl Peptidase 4 Inhibitor Treatment: A Longitudinal Study Using a French Public Health Insurance Database
INTRODUCTION: Diabetes is a growing epidemic that imposes a substantial economic burden on healthcare systems. This study aimed to evaluate the cost of managing type 2 diabetes (T2D) with dipeptidyl peptidase 4 inhibitors (DPP4Is) using real-world data. METHOD: This longitudinal study used data from...
Autores principales: | Emery, Corinne, Torreton, Elodie, Dejager, Sylvie, Levy-Bachelot, Laurie, Bineau, Sébastien, Detournay, Bruno |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995803/ https://www.ncbi.nlm.nih.gov/pubmed/31953694 http://dx.doi.org/10.1007/s13300-020-00760-x |
Ejemplares similares
-
Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database
por: Detournay, Bruno, et al.
Publicado: (2015) -
Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis
por: Charbonnel, Bernard, et al.
Publicado: (2017) -
Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: Analysis of a French national hospital database
por: Boursier, Jérôme, et al.
Publicado: (2020) -
New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022) -
Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)